非那雄胺对前列腺微血管和增殖能力的影响

Effect of finasteride on prostatic microvessel and hyperplasia

目的 :观察非那雄胺对增生前列腺中微血管和增殖能力的影响。方法 :89例中、重度前列腺增生症手术病人分为 2组。非那雄胺组 4 3例 ,年龄(71±s12 )a ,用非那雄胺 5mg ,po ,qd ,术前服用 5～ 7d ;对照组 4 6例 ,不用药并用免疫组化S P法 ,对 2组术后前列腺组织标本进行CD3 4和PCNA的检测。结果 :非那雄胺组术中输血 6例 (14 % ) ,输血量 (2 8± 9)mL、术后继发性血尿 5例 (12 % ) ;对照组分别为 15例 (33% ) ,(87± 19)mL ,18例(39% ) ,(P <0 .0 5 )。 2组免疫组化血管数、血管内面积、血管壁面积分别为 (66.0± 1.9)条 ,(15 2 .3±1.8)cm2 ,(14 3.5± 1.9)cm2 和 (12 7.0± 2 .3)条 ,(338.8± 2 .3)cm2 ,(4 4 2 .5± 2 .3)cm2 (均P <0 .0 1)。其PCNA阳性表达分别为 2 3± 3和 4 7± 3(P <0 .0 1)。结论 :非那雄胺可通过抑制前列腺组织增殖和微血管形成 。

AIM: To observe the effect of finasteride on prostatic microvessel and hyperplasia METHODS: In the prospective clinical study, eighty nine patients with prostatic hyperplasia were divided randomly into two groups. Finasteride group ( n =43, age 71± s 12 a) was treated with finasteride 5 mg, po , qd for 5 7 d before taking operation and control group ( n =46, age 67 a±11 a) did not take any drug. The immunohistochemical method was used to determine the expressions of CD 34 and PCNA in two groups. RESULTS: In finasteride group, there were 6(14 %) patients of 43 to be transfusion of blood, the volume of blood was (28±9) mL; 5 patients (12 %) of 43 with secondary hemasturia, while in the control group, there were patients (33 %) of 46 to be transfusion of blood, the volume of blood was (87±19) mL; 18 patients (39 %) of 46 with secondary humaturia. The volume of blood transfusion and hematuria secondary to prostatic bleed of the treated group were much less than those of the control group. The results of immumohistochemistry revealed that microvessel density and its area in the finasteride group were much less than those of the control group. In two groups, the expression of PCNA was significantly different, it was 23±3 and 47±3 respectioely ( P <0.01). CONCLSION: Finasteride can prevent and reduce prostatic bleeding associated with prostatectomy (suprapubic) and TURP.